The latest Investing Matters Podcast episode with London Stock Exchange Group's Chris Mayo has just been released. Listen here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFaron Pharmaceuticals Share News (FARN)

Share Price Information for Faron Pharmaceuticals (FARN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 97.50
Bid: 95.00
Ask: 100.00
Change: 0.00 (0.00%)
Spread: 5.00 (5.263%)
Open: 96.00
High: 97.50
Low: 96.00
Prev. Close: 96.00
FARN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Joules nomad resigns; Pharma C loss narrows

Fri, 18th Nov 2022 19:49

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News:

----------

Joules Group - Leicestershire, England-based country lifestyle retailer - Peel Hunt LLP resigns as nominated adviser and broker with immediate effect. If replacement nominated adviser is not appointed within a month, admission of company's share to trading on AIM will be cancelled. Says "has no current intention of appointing a replacement nominated adviser". Joules on Wednesday named Interpath Ltd as administrators.

----------

Upland Resources Ltd - London-based oil and gas company - Says wholly owned subsidiaries UPL Saouaf Ltd and Upland N Tunisia Ltd give Nobel Petroleum USA Inc and Pennpetro Energy PLC seven days notice for termination of farm-out agreement. Says long stop date has passed without certain conditions contained in the agreement being fulfilled. Agreement allowed NPUSA to farm-in into Upland's Saouaf permit area in Tunisia. UPL Saouaf says application to renew Saouaf permit "under consideration".

----------

Pharma C Investments PLC - New Jersey-based early-stage investor in the medical cannabis industry - Pretax loss narrows to GBP124,000 in the six months to June 30 from GBP247,000 in the same period last year. Company recorded no revenue. Has GBP275,000 investment in Product Earth, made in November 2021. Says Product Earth has "significant growth potential" and can "consolidate its position as the leading UK-based marketing growth engine for the legal cannabis and related plant wellness industries." Chair Sharon Segal says "the directors believe that the market sector which the company is focused upon investing in is growing and will be of increasing importance and that the company is well placed to identify the right opportunities to explore."

----------

Faron Pharmaceuticals Ltd - Turku, Finland-based clinical-stage biopharmaceutical company - Amends warrants agreements with IPF Partners. The warrant price will now be the lower of EUR1.85 per share or price of any subscription fundraise undertaken by the company.

----------

By Chris Dorrell; chrisdorrell@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
21 Feb 2019 12:17

Faron "Very Encouraged" By Early Clevegen Trials In Cancer Patients

LONDON (Alliance News) - Faron Pharmaceuticals Ltd on Thursday said early results from a trial of its Clevegen cancer drug are encouraging.Shares in Faron were up 10% at 64.00 pence on said

Read more
21 Feb 2019 10:09

Faron Pharmaceuticals shares surge on latest Clevegen data

(Sharecast News) - Shares in Faron Pharmaceuticals were surging on Thursday morning, after it announced an update on early observations on immunity and clinical response of MATINS patients after administration of its 'Clevegen' product.

Read more
13 Feb 2019 12:20

Faron Pharmaceuticals Encouraged By Clever-1 Antibody Study Result

LONDON (Alliance News) - Faron Pharmaceuticals Ltd on Wednesday said new data supports the use of Clever-1 antibodies in re-activating an immune response to tumours.Shares in Faron were up

Read more
19 Dec 2018 11:07

Faron Pharmaceuticals pins some hope to YODA trial

(Sharecast News) - Clinical stage biopharmaceutical company Faron Pharmaceuticals issued interim results from its pharmacokinetic/dynamic 'YODA' study on Wednesday, examining various formulations of recombinant human interferon-beta (IFN-beta).

Read more
14 Dec 2018 15:57

Dosing begins in Faron's study of 'Clevegen' drug

(Sharecast News) - Clinical stage biopharmaceutical company Faron Pharmaceuticals announced on Friday that the first patient has successfully been dosed in the phase I/II MATINS study of Clevegen, its wholly-owned novel precision cancer immunotherapy drug.

Read more
5 Dec 2018 11:19

WINNERS & LOSERS SUMMARY: Ashtead Falls On US Economic Slowdown Worry

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Wednesday.----------FTSE 100 - up 2.7%. Japan's Takeda Pharmaceutical

Read more
5 Dec 2018 10:13

Traumakine treatment optimal for particular subgroup, Faron finds

(Sharecast News) - Clinical stage biopharmaceutical company Faron Pharmaceuticals has identified, by genetic testing, an "optimal subgroup" of acute respiratory distress syndrome (ARDS) patients for Traumakine treatment who showed a substantial reduction in mortality during the INTEREST trial, it announced on Wednesday.

Read more
5 Dec 2018 09:09

Faron Pharmaceuticals Finds "Optimal" Patient Group For Traumakine

LONDON (Alliance News) - Faron Pharmaceuticals Ltd shares jumped on Wednesday as the company said it identified an "optimal" subgroup of patients, with a certain genetic mutation, to be

Read more
3 Dec 2018 10:50

WINNERS & LOSERS SUMMARY: McColl's Retail Plunges After Profit Warning

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Monday.----------FTSE 100 - up 8.9%, Evraz, up 7.8%, up

Read more
3 Dec 2018 10:09

Faron Pharmaceuticals applies to begin Clevegen clinical trials

(Sharecast News) - Clinical stage biopharmaceutical company Faron Pharmaceuticals announced on Monday that its clinical trial application to conduct a Phase I/II study with 'Clevegen', its wholly-owned novel precision cancer immunotherapy drug in development for the treatment of selected metastatic or inoperable tumours, has been approved by the Finnish Medicines Agency (FIMEA).

Read more
6 Nov 2018 16:29

DIRECTOR DEALINGS: Faron Divisional Chief Medical Officer Buys Shares

LONDON (Alliance News) - Faron Pharmaceuticals Oy on Tuesday said VP Drug Development Chief Medical Officer Matti Karvonen acquired shares in the biopharmaceutical company.In a transaction

Read more
22 Oct 2018 15:32

Faron Reports Corticosteroids Interference In Traumakine Trial

LONDON (Alliance News) - Faron Pharmaceuticals Ltd said Monday that it has found evidence suggesting that corticosteroids used in parallel to its Traumakine treatment had a significant effect on a

Read more
17 Sep 2018 10:37

Faron Pharmaceuticals Submits Clinical Trial Application For Clevegen

LONDON (Alliance News) - Faron Pharmaceuticals Oy said Monday it has filed a clinical trial application for its cancer immunotherapy drug Clevegen.Clevegen, an anti-Clever-1 antibody, the a

Read more
13 Sep 2018 10:49

WINNERS & LOSERS SUMMARY: Retailers Hit As John Lewis Profit Collapses

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Thursday.----------FTSE 100 - WINNERS----------Royal Bank a

Read more
13 Sep 2018 10:30

Faron Pharmaceuticals Falls As Interim Loss Widens On Research Costs

LONDON (Alliance News) - Shares in Faron Pharmaceuticals Ltd dropped on Thursday after the company said its loss for the first half of its financial year increased on higher research were trading

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.